OrbiMed Advisors LLC's Form 4 filing
Damora Therapeutics, Inc. (DMRA) · filed Apr 17, 2023
- Accession no.
- 0000947871-23-000472
- Filed
- Apr 17, 2023, 5:28 PM ET
- Trade date
- Apr 13-17, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions. Open-market sales total $128.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | 10% Owner |
| OrbiMed Israel GP II, L.P.CIK 0001682090 | 10% Owner |
| OrbiMed Advisors Israel II LtdCIK 0001682093 | 10% Owner |
| OrbiMed Capital GP VII LLCCIK 0001760648 | 10% Owner |
| OrbiMed Genesis GP LLCCIK 0001808744 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 13, 2023 | Common Stock | SSaleDisposed | −703 | $1.82 | −$1,279.46 | 182,504 | Indirect | |
| Apr 13, 2023 | Common Stock | SSaleDisposed | −3,784 | $1.82 | −$6,886.88 | 981,863 | Indirect | |
| Apr 13, 2023 | Common Stock | SSaleDisposed | −9,459 | $1.82 | −$17,215.38 | 2,454,775 | Indirect | |
| Apr 14, 2023 | Common Stock | SSaleDisposed | −2,091 | $1.86 | −$3,889.26 | 180,413 | Indirect | |
| Apr 14, 2023 | Common Stock | SSaleDisposed | −11,245 | $1.86 | −$20,915.7 | 970,618 | Indirect | |
| Apr 14, 2023 | Common Stock | SSaleDisposed | −28,110 | $1.86 | −$52,284.6 | 2,426,665 | Indirect | |
| Apr 17, 2023 | Common Stock | SSaleDisposed | −660 | $1.97 | −$1,300.2 | 179,753 | Indirect | |
| Apr 17, 2023 | Common Stock | SSaleDisposed | −3,551 | $1.97 | −$6,995.47 | 967,067 | Indirect | |
| Apr 17, 2023 | Common Stock | SSaleDisposed | −8,878 | $1.97 | −$17,489.66 | 2,417,787 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.